To cite this paper use one of the standards below:
Galectins are a family of lectins that bind to β-galactosides and are characterized by the presence of one or two conserved carbohydrate recognition domains (CRDs). Based on their structural organization, galectins are classified into three subgroups: prototype, tandem-repeat, and chimera-type. The only known member of the chimera-type and the focus of this study, human galectin-3 (Gal-3), a globular protein composed of two antiparallel β-sheets: the S-sheet, consisting of six β-strands (S1–S6) that form the carbohydrate-binding site, and the F-sheet, comprising five β-strands (F1–F5). The CRD can accommodate linear oligosaccharides of up to four residues containing β-galactoside units, such as N-acetyllactosamine (LacNAc). Its binding affinity is highly dependent on the ligand structure, showing low affinity for lactose and high affinity for glycoproteins enriched with multiple LacNAc residues. The strong interaction with membrane-associated glycoproteins enables Gal-3 to play a critical role in cardiac fibrosis, thereby contributing to the progression of heart failure. Given its biological relevance, a detailed understanding of Gal-3’s protein-ligand interactions can support rational drug design and the development of effective therapies aimed at slowing or halting the progression of various diseases. In this context, the objective of this project is to perform a comprehensive analysis of the Gal-3 C61A mutant, evaluating its thermal stability and binding affinity for various ligands. The mutant is expected to exhibit greater stability in solution and a similar affinity for carbohydrates compared to the native form of Gal-3. Based on the insights obtained from the C61A mutant, we aim to produce a double mutant, Gal-3 C61A-W69Y, to evaluate the influence of the tryptophan residue on carbohydrate interactions. For this purpose, the Gal-3 C61A mutant was expressed in Escherichia coli BL21 (DE3) at 18°C, yielding high expression levels of the soluble protein form. The protein was then purified using gel filtration chromatography. Subsequently, intrinsic tryptophan fluorescence spectroscopy was employed to evaluate the thermal stability of the unbound form of Gal-3, by gradually increasing the temperature from 20 °C to 50 °C. To assess Gal-3's binding affinity to different sugars, the sample was titrated with eight concentrations of four carbohydrates: galactose, N-acetylgalactosamine, lactose, and N-acetyllactosamine. Following the final concentration of each ligand, the temperature was again gradually increased from 20 °C to 50 °C. The results obtained were analyzed and compared to our previous data on wild-type human Gal-3 CRD. Based on the fluorescence emission intensity and the center of mass under each condition, we conclude that the Gal-3 C61A mutant displays distinct characteristics from native Gal-3. The 1H/15N HSQC showed similar features as the WT but some differences in few resonances were also observed. We are currently analyzing the relaxation parameters and compared it to the WT results. As future perspectives, we aim to characterize the ligand binding parameters of the Gal-3 C61A mutant using fluorescence spectroscopy and nuclear magnetic resonance. We are also moving on to the expression of the double mutant Gal-3 C61A-W69Y, using the same protocol, the protein was found to be insoluble in aqueous solution. To proceed with the experiments, an effective extraction and dialysis protocol is currently being developed to enable protein purification.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper